कंपनी का अवलोकन
Aytu BioPharma, Inc. is a pharmaceutical entity dedicated to the commercialization of novel therapeutics across the United States and international markets. The company operates within the healthcare sector, specifically functioning in the drug manufacturers – specialty & generic industry, which implies a focus on developing and selling specific medical treatments rather than broad pharmaceutical portfolios. Its operational scale is defined by a market capitalization of $27.48M, an annual revenue of $62.64M, and a workforce comprising 82 employees. These financial metrics indicate that Aytu BioPharma operates as a micro-cap entity with a relatively modest revenue base, suggesting it occupies a niche position in the specialty drug market rather than competing with large-scale generic drug manufacturers. The combination of a low market cap and sub-$65M revenue highlights the company's limited market penetration and resource constraints typical of firms focusing on specialized indications like ADHD treatment.
वित्तीय स्वास्थ्य
The company reported revenue of $62.64M over the trailing twelve months, yet it recorded a net income of -$24,559,000, revealing a significant gap between top-line sales and bottom-line profitability that points to substantial cost structures or one-time charges impacting the bottom line. While the EBITDA stands at $4.03M, indicating operational cash generation before interest, taxes, depreciation, and amortization, the free cash flow is -$6,978,375, which suggests the company is consuming cash reserves to fund operations or growth initiatives rather than generating surplus liquidity. The gross margin stands at 66.8%, indicating high pricing power or low cost of goods sold relative to revenue, whereas the operating margin is -13.0% and the profit margin is -39.0%, signaling that significant overhead costs or R&D expenses are eroding profitability before reaching the net income line. On the balance sheet, the company holds $30.02M in cash against $22.10M in debt, resulting in a debt-to-equity ratio of 155.63, which characterizes a highly leveraged financial position where equity is negative or minimal relative to obligations. Despite the high leverage, the current ratio of 1.16 indicates that the company maintains sufficient short-term assets to cover its short-term liabilities, though the buffer is tight. The return on equity is -109.2% and the return on assets is -0.2%, metrics that reveal management has been ineffective at generating positive returns on the shareholders' capital and the company's asset base, respectively, over the reported period.
मूल्यांकन आकलन
The company does not have a trailing P/E ratio available, but it trades with a forward P/E of 15.06, implying that the market expects earnings to turn positive or grow significantly to justify this valuation multiple in the future. The price-to-book ratio is 1.93, which suggests the market values the company at nearly double its book value, indicating a premium placed on its intangible assets or future pipeline despite current losses. Alternative valuation metrics such as a price-to-sales ratio of 0.44 and an EV/EBITDA of 4.86 provide context for valuation when earnings are negative, showing that investors are pricing the stock based on revenue generation and operational cash flow potential rather than current profitability. The stock has a 52-week high of $3.07 and a 52-week low of $0.96; without the specific current price provided in the facts, the trading position relative to this range cannot be precisely calculated, but the wide range of over $2.00 demonstrates significant price volatility over the last year. The beta value is 0.28, which indicates that the stock's price volatility is significantly lower than the broader market, suggesting it behaves as a low-volatility asset that moves independently of general market trends.
Growth & Income
The revenue growth year-over-year is -6.5%, while earnings growth is listed as N/A due to the negative net income, implying that the company is currently contracting in revenue and has not yet achieved a trajectory of positive earnings expansion. Since the company does not pay dividends, with a dividend yield of N/A and a payout ratio of 0.0%, it retains all available cash flow to reinvest into its drug development pipeline or to reduce its substantial debt burden rather than distributing income to shareholders. The overall growth and income profile is characterized by negative revenue expansion and zero dividend income, reflecting a phase where the company prioritizes capital allocation toward commercializing novel therapeutics over returning value to investors. This profile aligns with a speculative investment thesis where capital appreciation depends entirely on future earnings turnaround rather than current income generation or consistent revenue growth.